Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 3 6Phase 2 5Phase 1/2 5

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 28NIH 5INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 3Sarcoma 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Osteosarcoma 1Neoplasms 1Lymphoma, Follicular 1B-Cell Malignancies 1

Interventions

pembrolizumab 242Carboplatin 135Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Bevacizumab 95Cyclophosphamide 93Dexamethasone 78Injections 75Docetaxel 72Pemetrexed 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 60130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 56Ipilimumab 54fludarabine 47Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Ifosfamide × Clear all
NCT04663347 2026-05-05

EPCOREâ„¢ NHL-2

Genmab

Phase 1/2 Active not recruiting
543 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05533775 2026-05-04

iMATRIX GLO

Hoffmann-La Roche

Phase 1/2 Recruiting
65 enrolled

Recurrence

NCT02348216 2024-06-04

ZUMA-1

Gilead Sciences

Phase 1/2 Completed
307 enrolled 41 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02018861 2023-09-28

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Incyte Corporation

Phase 1/2 Completed
88 enrolled 25 charts
Lymphoid

B-Cell Malignancies

NCT02432274 2023-07-11

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Eisai Inc.

Phase 1/2 Completed
117 enrolled 32 charts
Sarcoma

Neoplasms, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡